Myocardial 123I-metaiodobenzylguanidine scintigraphy in patients with homozygous and heterozygous parkin mutations
- 1 December 2015
- journal article
- case report
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 24 (1) , 103-107
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Parkinson's disease with Lewy bodies associated with a heterozygous PARKIN dosage mutationMovement Disorders, 2013
- Observer reproducibility of results from a low-dose 123I-metaiodobenzylguanidine cardiac imaging protocol in patients with heart failureEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- Lewy body pathology in a patient with a homozygous Parkin deletionMovement Disorders, 2013
- The neuropathology of genetic Parkinson's diseaseMovement Disorders, 2012
- Reduced cardiac uptake and enhanced washout of 123I-MIBG in pure autonomic failure occurs conjointly with Parkinson's disease and dementia with Lewy bodies.2006
- Neurophysiological evidence of corticospinal tract abnormality in patients with Parkin mutationsJournal of Neurology, 2006
- Preserved myocardial [123I]metaiodobenzylguanidine uptake in autosomal recessive juvenile parkinsonism: First case reportMovement Disorders, 2005
- Steele‐Richardson‐Olszewski syndrome in a patient with a single C212Y mutation in the parkin proteinMovement Disorders, 2002
- Complex relationship between Parkin mutations and Parkinson diseaseAmerican Journal of Medical Genetics, 2002
- The parkin gene and its phenotypeNeurological Sciences, 2001